Overview of NDC 23155-0857
The National Drug Code (NDC) 23155-0857 corresponds to the drug Anastrozole, which is manufactured by Heritage Pharmaceuticals Inc., doing business as Avet Pharmaceuticals Inc.[4].
Drug Description
Anastrozole is a non-steroidal aromatase inhibitor used primarily in the treatment of breast cancer. It works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By reducing estrogen levels, Anastrozole helps to slow or stop the growth of hormone-sensitive breast cancer cells.
Market Context
Pharmaceutical Market Growth
The US pharmaceutical market, which includes drugs like Anastrozole, is projected to grow significantly. From $846.72 billion in 2022, the market is expected to reach $1.28 trillion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.36%[3].
Specialty Pharmaceuticals
Specialty pharmaceuticals, including those for cancer treatment, are a significant driver of this growth. These drugs, which treat complex or chronic conditions, are expected to see a price increase of 4.18% in 2024, driven by factors such as the increasing utilization of new therapies and the expansion of gene therapies[2].
Price Trends
While specific price data for NDC 23155-0857 (Anastrozole) is not readily available in the provided sources, we can infer some trends from related data:
General Drug Price Inflation
The overall drug price inflation is projected to be 3.8% in 2024, with specialty pharmaceuticals contributing significantly to this increase. This trend suggests that prices for drugs like Anastrozole could also rise, although at a potentially lower rate compared to newer specialty drugs[2].
Generic and Biosimilar Impact
The increasing approvals of generic drugs and the growing market share of biosimilars can influence the pricing of branded and generic versions of drugs. However, since Anastrozole is already a generic drug, its price may be less affected by these factors compared to branded drugs. For instance, biosimilars are expected to increase in price by only 0.55%, which could stabilize or slightly reduce the prices of their corresponding generic drugs[2].
Supply Chain and Availability
FDA Oversight
The FDA's National Drug Code Directory ensures that all finished and unfinished drugs, including Anastrozole, are properly listed and regulated. This oversight helps maintain the quality and availability of these drugs in the market[1].
Manufacturer and Labeler
Heritage Pharmaceuticals Inc., doing business as Avet Pharmaceuticals Inc., is responsible for manufacturing and labeling Anastrozole under the NDC 23155-0857. The company's compliance with FDA regulations and its production capacity can impact the drug's availability and pricing[4].
Price Projections
Given the general trends in the pharmaceutical market:
- Short-term Projections: Prices for Anastrozole (NDC 23155-0857) are likely to remain stable or see a modest increase, aligning with the overall 3.8% drug price inflation projected for 2024.
- Long-term Projections: As the US pharmaceutical market continues to grow, driven by increasing demand and advancements in drug discovery, prices for established generic drugs like Anastrozole may experience slower growth compared to newer, specialty pharmaceuticals.
Key Takeaways
- Market Growth: The US pharmaceutical market is expected to grow significantly, driven by rising demand and advancements in drug discovery.
- Price Trends: General drug price inflation is projected at 3.8% in 2024, with specialty pharmaceuticals driving this increase.
- Generic Drug Prices: Prices for generic drugs like Anastrozole are likely to remain stable or see modest increases.
- Regulatory Oversight: FDA's National Drug Code Directory ensures the quality and availability of drugs in the market.
FAQs
Q: What is the primary use of Anastrozole (NDC 23155-0857)?
A: Anastrozole is primarily used in the treatment of breast cancer by inhibiting the enzyme aromatase, which reduces estrogen levels.
Q: Who manufactures Anastrozole under NDC 23155-0857?
A: Heritage Pharmaceuticals Inc., doing business as Avet Pharmaceuticals Inc., manufactures Anastrozole under this NDC.
Q: What is the projected growth rate of the US pharmaceutical market?
A: The US pharmaceutical market is projected to grow at a CAGR of 5.36% from 2022 to 2030.
Q: How do biosimilars affect the pricing of generic drugs?
A: Biosimilars can stabilize or slightly reduce the prices of their corresponding generic drugs, as seen with a projected price increase of only 0.55% for biosimilars.
Q: What factors drive the price increase in specialty pharmaceuticals?
A: The increasing utilization of new therapies, the expansion of gene therapies, and the treatment of complex or chronic conditions drive the price increase in specialty pharmaceuticals.
Sources
- FDA's National Drug Code Directory - FDA
- Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals - Vizient, Inc.
- US Pharmaceutical Market Review 2020-2023 and Forecast - GlobeNewswire
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. - FindACode
